Sign in
Not yet recruitingPhase 3

Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC)

Key facts

Who runs it
Dr. Falk Pharma GmbH
Where
Austria, Belgium, Denmark, France, Germany, Hungary, Netherlands, Norway, Poland, and Sweden22 sites in 10 countriesChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 3
People taking part
120 people, planned
Started
Mar 2025
Expected to end
Sept 2027
Type of study
Interventional
Treatments tested
  • norucholic acid
Record updated
20 March 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Signed informed consent
  • Males or females ≥ 18 years
  • Patient has previously been diagnosed with PSC, has participated in the previous NUC 5/PSC trial and has completed the DBE phase with Visit 22, or has prematurely terminated the DBE phase before this trial has been started, or has prematurely terminated the DBE phase after this trial has been started, under the condition that the premature termination was due to lack of efficacy*. (*Lack of efficacy as defined in the NUC-5/PSC trial.)

Who cannot take part

  • Patients who discontinued study participation in NUC-5/PSC due to an AE possibly caused by the study drug
  • History of liver transplantation or patient listed for transplantation
  • History or presence of chronic alcoholic consumption (daily consumption > 30 g in men, > 20 g in women)
  • Liver Cirrhosis or any cirrhosis-related symptoms which in the opinion of the investigator may affect the patient's safety

This trial has no sites in United States.

It has sites in 10 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

Open-label, multi-center, phase III trial. Oral treatment with 1500 mg norucholic acid in Primary Sclerosing cholangitis

The group in the trial

  • norucholic acid 1500 mg/dayTreatment being tested

    3 film-coated tablets once daily for 72 weeks containing in total norUrsodeoxycholic acid 1500 mg

    Treatment: norucholic acid

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
An Open-label Study of Patients with Primary Sclerosing Cholangitis (PSC) Treated with Norucholic Acid Tablets
Record updated
20 March 2025